Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2022 16:01 ET | Source: HiberCell, Inc.

HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today...
May 24, 2022 08:00 ET | Source: HiberCell, Inc.

HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today announced...
April 28, 2022 08:00 ET | Source: HiberCell, Inc.

HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutic candidates to address therapeutic resistance, cancer relapse and metastasis,...
March 03, 2022 08:00 ET | Source: HiberCell, Inc.

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment

In-person presentation taking place Wednesday, March 9, in the session beginning at 5:00pm MSTPresentation in Trained Immunity in Disease Treatment Session at Keystone Symposia in Banff, AB,...
February 24, 2022 08:00 ET | Source: HiberCell, Inc.

HiberCell Initiates its Phase 1a/b Clinical Trial of HC-7366 in Patients with Advanced Solid Tumors

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, has initiated...
December 14, 2021 08:00 ET | Source: HiberCell

HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Breast Cancer

NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today...
December 07, 2021 10:58 ET | Source: HiberCell

HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium

Open-label phase 2 clinical trial is actively recruiting new patients and opening new sitesResults to be presented in a poster session at SABCS 2021 on December 8, 2021NEW YORK, Dec. 07, 2021 (GLOBE...
September 30, 2021 08:00 ET | Source: HiberCell

HiberCell Appoints Jonathan Lanfear as Chief Operating Officer

Expands Board of Directors with Appointment of Cindy Jacobs, PhD, MD NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat...
September 08, 2021 08:00 ET | Source: HiberCell

HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU

NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced today that the U.S. Food and...
August 16, 2021 08:00 ET | Source: HiberCell

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

NEW YORK and BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced today the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right